Connect Biopharma Holdings Limited
NASDAQ:CNTBBiotechnology
Healthcare
$0.80 -4.09%
-$0.09 today
- Market cap
- $50.52M
- Beta
- -0.21
- P/E (TTM)
- -4.0
- EPS (TTM)
- -$0.50
52W Low $0.91High $3.82
Volume 2.50M
Average 0.30M
Income Statement
Follow revenue through to earnings.
Revenue
$64,000.00
FY 2025 · Annual
-99.8% YoYOperating Income
-$58.07M
FY 2025 · Annual
Net Income
-$55.48M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 26.03M | 64K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 26.03M | 64K |
| Gross Margin | — | — | — | 100.0% | 100.0% |
| Research & Development | 80.5M | 96.63M | 53M | 29.26M | 37.8M |
| Selling, General & Admin | 19.01M | 20.81M | 16.05M | 19.23M | 20.34M |
| Operating Expenses | 98.11M | 119.32M | 69.06M | 48.49M | 58.14M |
| Depreciation & Amortization | 634K | 1.03M | 720K | 660K | 704K |
| EBITDA | (201.36M) | (116.74M) | (61.27M) | (14.75M) | (54.58M) |
| EBITDA Margin | — | — | — | -56.6% | -85279.7% |
| Operating Income | (98.11M) | (119.32M) | (69.06M) | (22.45M) | (58.07M) |
| Operating Margin | — | — | — | -86.2% | -90740.6% |
| Interest Income | 97.67K | 1.56M | 5.2K | 4.45M | 2.27M |
| Interest Expense | 6.91K | 21.03K | 0 | 0 | 0 |
| Other Income / Expenses | (103.89M) | 1.52M | 7.07M | 7.05M | 2.79M |
| Income Before Tax | (202M) | (117.79M) | (61.99M) | (15.41M) | (55.28M) |
| Pre-Tax Margin | — | — | — | -59.2% | -86379.7% |
| Income Tax Expense | 266K | 298K | 120K | 223K | 197K |
| Net Income | (202.27M) | (118.09M) | (62.11M) | (15.63M) | (55.48M) |
| Net Margin | — | — | — | -60.0% | -86687.5% |
| EPS (Basic) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| EPS (Diluted) | (25.00) | (14.50) | (1.08) | (0.28) | (1.00) |
| 52.27M | 55.04M | 55.07M | 55.21M | 55.66M | |
| 52.27M | 55.04M | 55.07M | 55.21M | 55.66M |
CNTB Earnings Waterfall · TTM
NASDAQ:CNTB · Revenue to Net Income
Key Ratios
EPS$-0.78
Gross Margin75.0%
Net Margin-7021.8%
P/E Ratio-1.1
P/S Ratio311.4
Analysis
$24.9M of revenue converted into -$22.1M of net income for the selected period. Gross margin is 75.0% and net margin is -7021.8%, showing how much revenue survives after costs and taxes. EPS is $-0.78, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Oct 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 1, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 1, 2026 | |
| 8-K | Current report | Sep 30, 2026 | |
| 8-K | Current report | Sep 15, 2026 |
How much revenue does CNTB generate?
Connect Biopharma Holdings Limited (CNTB) reported $64,000.00 of revenue in fiscal 2025.
Is CNTB profitable?
Connect Biopharma Holdings Limited (CNTB) reported -$55.48M of net income, with a net margin of -86687.5%.
Continue the stock analysis
Jump to another research area for this company.